Age-related macular degeneration (AMD) is the most common cause of
blindness for individuals age 50 and above in the developed world. Abnormal growth of choroidal blood vessels, or
choroidal neovascularization (CNV), is a hallmark of the neovascular (wet) form of advanced AMD and leads to significant vision loss. A growing body of evidence supports a strong link between neovascular disease and
inflammation. Metabolites of long-chain
polyunsaturated fatty acids derived from the
cytochrome P450 (CYP)
monooxygenase pathway serve as vital second messengers that regulate a number of
hormones and
growth factors involved in
inflammation and vascular function. Using transgenic mice with altered CYP
lipid biosynthetic pathways in a mouse model of
laser-induced CNV, we characterized the role of these
lipid metabolites in regulating neovascular disease. We discovered that the CYP-derived
lipid metabolites epoxydocosapentaenoic
acids (EDPs) and epoxyeicosatetraenoic
acids (EEQs) are vital in dampening CNV severity. Specifically, overexpression of the
monooxygenase CYP2C8 or genetic ablation or inhibition of the soluble
epoxide hydrolase (sEH)
enzyme led to increased levels of EDP and EEQ with attenuated CNV development. In contrast, when we promoted the degradation of these CYP-derived metabolites by transgenic overexpression of sEH, the protective effect against CNV was lost. We found that these molecules work in part through their ability to regulate the expression of key
leukocyte adhesion molecules, on both leukocytes and endothelial cells, thereby mediating leukocyte recruitment. These results suggest that CYP
lipid signaling molecules and their regulators are potential therapeutic targets in neovascular diseases.